Daily Ards Research Analysis
Analyzed 9 papers and selected 3 impactful papers.
Summary
Three complementary studies advance ARDS research: a meta-analysis supports EIT-guided personalized PEEP to improve oxygenation and compliance; a pediatric ARDS secondary analysis shows diaphragm thickening fraction fails to predict effort or weaning; and a translational study identifies the miR-548a-3p–OSM axis as a potential diagnostic/prognostic biomarker and mechanistic pathway.
Research Themes
- Personalized ventilation with EIT-guided PEEP
- Validation of bedside ultrasound metrics for weaning
- Translational biomarkers and fibrosis-related mechanisms in ARDS
Selected Articles
1. Personalized positive-end expiratory pressure using electrical impedance tomography in ARDS patients: a systematic review and meta-analysis.
Across nine studies (n=356), EIT-guided PEEP titration improved oxygenation and respiratory system compliance in adults with ARDS. The review was PRISMA-compliant and protocol-registered, but patient-centered outcomes remain insufficiently studied due to heterogeneity and small samples.
Impact: Provides consolidated evidence supporting physiology-based personalization of PEEP using EIT in ARDS. Guides clinical adoption and research prioritization beyond single-center trials.
Clinical Implications: EIT-guided PEEP titration can be used to personalize ventilatory settings to improve oxygenation and compliance in ARDS. Implementation should be coupled with standardized training and protocols, while awaiting trials assessing mortality, ventilator-free days, and weaning outcomes.
Key Findings
- EIT-guided PEEP improved oxygenation (PaO2/FiO2) compared with conventional titration across pooled studies.
- Respiratory system compliance improved under EIT-guided strategies.
- The review followed PRISMA 2020, was PROSPERO-registered, and included 9 studies (n=356), but heterogeneity and limited patient-centered outcomes remain.
Methodological Strengths
- PRISMA-compliant, PROSPERO-registered protocol
- Included both randomized and observational evidence with predefined outcomes
Limitations
- Small cumulative sample size (n=356) and study heterogeneity
- Limited reporting of hard clinical outcomes (mortality, ventilator-free days)
Future Directions: Conduct adequately powered multicenter RCTs comparing EIT-guided versus conventional PEEP titration with patient-centered outcomes and standardized training/protocols.
OBJECTIVE: Personalized mechanical ventilation strategies can improve outcomes in patients with Acute Respiratory Distress Syndrome (ARDS). However, the optimal method for titrating positive end-expiratory pressure (PEEP) remains controversial. Electrical Impedance Tomography (EIT), by enabling real-time, regional assessment of lung regional characteristics, offers potential advantages to guiding PEEP titration as compared to conventional methods. DATA SOURCES AND STUDY SELECTION: We conducted a systematic review and meta-analysis of randomized clinical trials and observational studies comparing EIT-guided versus conventional PEEP titration in adult ARDS. The review was conducted according to the PRISMA 2020 guidelines. Moreover, the review was conducted in accordance with the MOOSE (Meta-analysis of Observational Studies in Epidemiology) recommendations, where applicable, and with the registered protocol (PROSPERO ID: CRD420251015187). The primary outcomes were the PaO DATA EXTRACTION AND DATA SYNTHESIS: Nine studies (n = 356 patients) were included. EIT-guided PEEP titration was associated with an improvement in oxygenation, expressed as PaO CONCLUSION: EIT-guided PEEP titration improves oxygenation and respiratory system compliance in patients with ARDS, supporting its role as a physiology-based strategy for ventilatory personalization. Further evidence are needed to determine whether these physiological improvements translate into better clinical outcomes.
2. Diaphragm Thickening Fraction Fails to Predict Esophageal Pressure or Ventilator Weaning in Children.
In a secondary analysis of 194 pediatric ARDS patients with 704 measurements, daily diaphragm thickening fraction had a weak correlation with esophageal pressure (r=0.10) and failed to predict SBT or extubation outcomes (AUC 0.54). DTF should not be used in isolation to guide weaning decisions in children.
Impact: Provides rigorous negative evidence against using DTF as a surrogate for effort or weaning readiness in pediatric ARDS, directly informing bedside practice.
Clinical Implications: Avoid relying on DTF alone for weaning/extubation decisions in children; integrate clinical assessment with objective measures (e.g., esophageal pressure, work of breathing) and standardized SBT protocols.
Key Findings
- Daily DTF correlated poorly with esophageal pressure (r=0.10; 95% CI 0.01-0.19).
- No significant difference in SBT DTF between early failures, late failures, and successes (P=0.69).
- DTF during SBT did not predict extubation outcomes (AUC=0.54; 95% CI 0.44-0.64).
Methodological Strengths
- Prospective daily physiologic measurements including dPes and ultrasound
- Standardized SBT conditions and predefined outcome definitions
Limitations
- Single-center secondary analysis limits generalizability
- Pediatric population; findings may not extrapolate to adults
Future Directions: Evaluate composite weaning indices incorporating effort measures, neural drive, and diaphragmatic function; explore age-specific thresholds and multicenter validation.
BACKGROUND: Studies relating diaphragm thickening fraction (DTF), delta esophageal pressure (dPes), and weaning outcomes are lacking in critically ill children. RESEARCH QUESTION: How well does DTF correlate with dPes and predict weaning/extubation outcomes? STUDY DESIGN AND METHODS: Secondary analysis of children with ARDS from a single-center randomized control trial. DTF and dPes were measured daily during mechanical ventilation and during spontaneous breathing trials (SBT, CPAP 5 cmH RESULTS: There were 194 patients with 704 Daily measurements. The correlation between the Daily DTF and dPes was r = 0.10 (95% CI = 0.01-0.19). There were 171 successful SBTs, 60 early failures, and 88 late failures, with no difference in the median SBT DTF between groups (Early Failure: 20% (10, 32), Late Failure: 18% (12, 26), Success: 19% (11, 28), P = 0.69). The SBT DTF was not predictive of extubation success or failure (reintubation or prolonged NIV) (AUC = 0.54, 95% CI = 0.44-0.64), with the median SBT DTF of 19% (IQR = 11-31, n = 124) for those successfully extubated; 23% (IQR = 16-30, n = 12) for those reintubated; and 17% (IQR = 10-23, n = 30) for those who received prolonged NIV (P = 0.3). INTERPRETATION: DTF should be used with caution in children as it does not appear to have a strong correlation with measures of respiratory effort and does not reliably predict SBT or extubation outcomes.
3. Clinical significance of miR-548a-3p and its potential role in acute respiratory distress syndrome complicated with pulmonary fibrosis via OSM.
Serum miR-548a-3p was decreased in ARDS, negatively correlated with IL-6/IL-8, and discriminated ARDS from healthy controls with prognostic value. Mechanistically, miR-548a-3p targets oncostatin M; its overexpression mitigated inflammation and apoptosis in LPS-injured BEAS-2B cells, effects reversed by OSM overexpression.
Impact: Identifies a novel miRNA–cytokine axis (miR-548a-3p–OSM) in ARDS with both diagnostic/prognostic implications and mechanistic support, bridging clinical biomarker discovery and basic biology.
Clinical Implications: miR-548a-3p could serve as a serum biomarker for ARDS diagnosis and prognosis and highlights OSM as a potential therapeutic target, pending external validation and prospective trials.
Key Findings
- Serum miR-548a-3p levels are reduced in ARDS and inversely correlate with IL-6/IL-8.
- miR-548a-3p discriminates ARDS from healthy controls and has prognostic value (Kaplan–Meier/Cox analyses).
- miR-548a-3p directly targets OSM; overexpression reduces inflammation and apoptosis in LPS-injured BEAS-2B cells, effects reversed by OSM overexpression.
Methodological Strengths
- Integrates clinical serum biomarker analyses with mechanistic in vitro validation
- Multiple orthogonal assays (RT-qPCR, ELISA, dual-luciferase, functional cell assays)
Limitations
- Clinical sample size and cohort characteristics not fully detailed in the abstract
- Translational findings require external validation and in vivo confirmation
Future Directions: Validate miR-548a-3p diagnostic/prognostic performance in multicenter cohorts, explore longitudinal dynamics, and assess OSM-targeted interventions in preclinical models.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is characterized by acute diffuse lung injury, with pulmonary fibrosis (PF) being a significant complication. The expression patterns and functional role of miR-548a-3p in ARDS and associated PF remain unexplored. PURPOSE: This study aims to delineate the diagnostic and prognostic significance of miR-548a-3p in ARDS and elucidate its underlying molecular mechanisms. METHODS: Serum miR-548a-3p levels in ARDS patients were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Diagnostic value was evaluated via receiver operating characteristic (ROC) curves and binary logistic regression, and prognostic significance via Kaplan-Meier analysis and Cox regression. Interleukin-6 (IL-6)/Interleukin-8 (IL-8) levels were measured via enzyme-linked immunosorbent assay (ELISA). Potential targets were screened (NCBI/miRDB) and binding validated by dual-luciferase reporter assays. In lipopolysaccharide (LPS)-injured BEAS-2B cells, miR-548a-3p/Oncostatin M (OSM) regulation effects were examined via ELISA, Cell Counting kit-8 (CCK-8), and flow cytometry. RESULTS: ARDS patients exhibited decreased miR-548a-3p expression, which correlated negatively with IL-6 and IL-8. Furthermore, miR-548a-3p effectively discriminated between ARDS patients and healthy individuals and served as a predictor of ARDS. In LPS-injured BEAS-2B cells, miR-548a-3p overexpression promoted proliferation, suppressed apoptosis, and reduced inflammation. OSM was identified as a direct target of miR-548a-3p through database screening and experimental validation. OSM overexpression reversed the protective effects of miR-548a-3p on LPS-injured lung epithelial cells. CONCLUSIONS: This study is the first to reveal that miR-548a-3p exerts protective effects in ARDS by targeting OSM, underscoring its great potential as a novel diagnostic and prognostic biomarker.